Regulatory Open Forum

 View Only
  • 1.  MDR/IVDR PMS Plan - Include devices sold in other jurisdictions?

    This message was posted by a user wishing to remain anonymous
    Posted 16-Feb-2022 20:50
    This message was posted by a user wishing to remain anonymous

    A manufacturer has a single device available in multiple jurisdictions, with the same design and intended use. Is the manufacturer required to include the devices that are not CE-marked and sold in other jurisdictions in the scope of the MDR/IVDR PMS Plan?


  • 2.  RE: MDR/IVDR PMS Plan - Include devices sold in other jurisdictions?

    Posted 16-Feb-2022 22:15
    Hi Anon

    MDR Article 83 doesn't suggest it should be limited to EU jurisdictions. It says the process needs to be part of the quality management system, which suggests something universal. Since one purpose is to detect a need for preventive action, I'd imagine in most cases you'd want to consider things going wrong wherever they might be.

    Would the effort involved in gathering data in those places be onerous out of proportion with the risk of the device? You're probably already handling complaints for every jurisdiction.

    ------------------------------
    Anne LeBlanc
    United States
    ------------------------------



  • 3.  RE: MDR/IVDR PMS Plan - Include devices sold in other jurisdictions?

    Posted 17-Feb-2022 05:10
    Hello Anon,

    I support what Anne says is although post market surveillance in the EU MDR/IVDR does not say Europe/European Union specifically, there is implied context it applies universally to the product distribution.  Most regulatory agencies have that approach as well.  Because now post market surveillance is an "active" process meaning being aware of what is happening with your products in the market.  Therefore, say a company manufacturing in United States and ships/distributes in Europe, encounters an issue in the United States after few days of releasing a product.  If the product is still in transit or warehouse in Europe, then it could be anticipated or stopped from further distribution.  Also the analysis of the data is important because if there is a large sales volume in United States and very small in Europe, than analysing only Europe may not give an indicator or as Anne said the proportion is out of keel with the rest of the volume distribution.  With that said, as part of post market surveillance (depends on type of device) we usually conduct analysis for all markets and then do a subset of Europe, e.g. 2 or 3 adverse events in U.S., but nothing in Europe so conducting almost a comparison.

    ------------------------------
    Richard Vincins ASQ-CQA, MTOPRA, RAC
    Vice President Global Regulatory Affairs
    ------------------------------



  • 4.  RE: MDR/IVDR PMS Plan - Include devices sold in other jurisdictions?

    Posted 17-Feb-2022 08:32

    In general, the answer is yes; PMS should look at post-market information regardless of regulatory region. PMS is concerned with how the device performs clinically and that information typically doesn't respect national or regional boundaries.

    Consider, as an example, the form for a vigilance report. It requires global sales information based on IMDRF codes, not just EU information.



    ------------------------------
    Dan O'Leary CQA, CQE
    Swanzey NH
    United States
    ------------------------------